Table 1.
Patient characteristics and clinical outcomes
| Patient ID | Age | Race | Sex | Stage at diagnosis | Previous therapy | Site of active disease at time of study enrollment | Dose level | EBV-CTL response |
|---|---|---|---|---|---|---|---|---|
| P1507 | 39 | A | M | T4N1M0 (IVA) | CT ×2, XRT | Primary, bone, LN | 1 | SD × 12 mo |
| P1560 | 53 | C | F | T4N1M0 (IVA) | CT ×4, XRT | Primary, sinuses, temporal lobe | 1 | SD × 15 mo |
| P1641 | 14 | C | F | T4N1M1 (IVC) | CT ×1, XRT | Primary, bone, LN | 1 | PD |
| P1668 | 17 | B | M | T4N2M0 (IVA) | CT ×3, XRT | Bone, LN | 2 | PD |
| P1708 | 38 | C | F | T4N1M0 (IVA) | CT ×2* | Primary, bone, LN, lung, parotid gland | 2 | PD |
| P1740 | 15 | C | F | T2bN2M0 (III) | CT ×4, XRT | Primary | 2 | CR > 24 mo |
| P1790 | 64 | C | M | T4N2M0 (IVA) | CT ×2, XRT | Bone, LN, lungs | 3 | PD |
| P1798 | 40 | A | M | T4N1M0 (IVA) | CT ×4, XRT | Bone, LN, liver | 3 | PD |
A indicates Asian; B, black; C, Caucasian; M, male; F, female; mo, months; CT × n, where n is the number of previous chemotherapy regimens; XRT, radiotherapy; *, refused XRT; CR, complete response; PR, progressive disease; and SD, stable disease.